These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1489 related articles for article (PubMed ID: 33657295)

  • 41. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
    Neal J; Pavlakis N; Kim SW; Goto Y; Lim SM; Mountzios G; Fountzilas E; Mochalova A; Christoph DC; Bearz A; Quantin X; Palmero R; Antic V; Chun E; Edubilli TR; Lin YC; Huseni M; Ballinger M; Graupner V; Curran D; Vervaet P; Newsom-Davis T
    J Clin Oncol; 2024 Jul; 42(20):2393-2403. PubMed ID: 38552197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
    Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
    Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
    Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
    Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
    Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
    JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
    Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
    J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
    Allaf ME; Kim SE; Master V; McDermott DF; Harshman LC; Cole SM; Drake CG; Signoretti S; Akgul M; Baniak N; Li-Ning E; Palmer MB; Emamekhoo H; Adra N; Kaimakliotis H; Ged Y; Pierorazio PM; Abel EJ; Bilen MA; Ogan K; Moon HH; Ramaswamy KA; Singer EA; Mayer TM; Lohrey J; Margulis V; Gills J; Delacroix SE; Waples MJ; James AC; Wang P; Choueiri T; Michaelson MD; Kapoor A; Heng DY; Shuch B; Leibovich BC; Lara PN; Manola J; Maskens D; Battle D; Uzzo R; Bratslavsky G; Haas NB; Carducci MA
    Lancet Oncol; 2024 Aug; 25(8):1038-1052. PubMed ID: 38942046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
    Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
    Front Public Health; 2022; 10():954264. PubMed ID: 36159269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
    Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
    Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
    Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
    Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
    Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
    Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
    Lara PN; Villanueva L; Ibanez C; Erman M; Lee JL; Heinrich D; Lipatov ON; Gedye C; Gokmen E; Acevedo A; Semenov A; Park SH; Gafanov RA; Kose F; Jones M; Du X; Munteanu M; Perini R; Choueiri TK; Motzer RJ
    BMC Cancer; 2024 Jul; 23(Suppl 1):1253. PubMed ID: 39054430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
    N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
    Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
    Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
    Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
    N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
    Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
    Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
    Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
    Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
    Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
    Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.